On a Mission to revolutionize mental healthcare

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Request Investor Info

This form collects information we will use to send you information on market news and insightful information for your portfolio. We will not share or sell your personal information. You can unsubscribe at any time.

As seen on BNN Bloomberg:

Why Invest?

  • C$88M raised to date. Well-funded to progress clinical trials, M&A, and IP strategies.
  • 4 active drug programs targeting Major Depressive Disorder, Alcohol Use Disorder, Anxiety Disorders, and other Psychiatric Disorders (CYB001, CYB003, CYB004, CYB005).
  • Phase II approval to commence clinical trial on CYB001 which is targeting Major Depressive Disorder.
  • 12 patent filings and growing which cover Novel psychedelic compounds, Integration of delivery platforms, and Methods of use in psychiatric indications.
  • A team with 30+ years of experience in the healthcare sector

Learn More about Cybin

Request Investor Info!

Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration, Health Canada, or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by approved research. There is no assurance that psilocybin can be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed.